Patents by Inventor Kazuyuki Sogawa

Kazuyuki Sogawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160370382
    Abstract: An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma.
    Type: Application
    Filed: July 22, 2016
    Publication date: December 22, 2016
    Applicant: NITTO BOSEKI CO., LTD.
    Inventors: Ryo KOJIMA, Kenta NODA, Masanori SEIMIYA, Kazuyuki SOGAWA, Fumio NOMURA
  • Patent number: 9017959
    Abstract: Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the ?-E chain and ? chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: April 28, 2015
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Wataru Kikuchi, Momoe Sato, Kenta Noda, Iwao Kiyokawa, Toshihide Miura, Ryo Kojima, Fumio Nomura, Kazuyuki Sogawa
  • Publication number: 20150104816
    Abstract: A marker for detecting pancreatic cancer, said marker comprising a glycoprotein C4BPA or PIGR, whereby a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and thus specifically diagnosed. Also, the marker is usable in monitoring the postoperative prognosis of a pancreatic cancer patient. When the aforesaid marker is used in combination with another pancreatic cancer marker such as CA19-9, furthermore, a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and diagnosed more specifically.
    Type: Application
    Filed: April 1, 2013
    Publication date: April 16, 2015
    Applicant: NITTO BOSEKI CO., LTD.
    Inventors: Kenta Noda, Toshihide Miura, Humio Nomura, Kazuyuki Sogawa, Mamoru Sato, Hideyuki Yoshitomi, Masaru Miyazaki
  • Patent number: 8563235
    Abstract: A method of detecting an abnormal amount of a biomarker associated with biliary tract cancer in a subject can comprise: a) quantitating an amount of a fragment of prothrombin having an m/z value of about 4204 m/z in a biological sample from the subject; and b) comparing the quantitated value obtained in (a) with a threshold value.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: October 22, 2013
    Assignee: National University Corporation Chiba University
    Inventors: Shintaro Kikkawa, Kazuyuki Sogawa, Osamu Yokosuka, Fumio Nomura
  • Publication number: 20120309034
    Abstract: A reaginic antibody of Ku86 and a substance capable of binding with the autoantibody of Ku86 are acted on a complex of Ku86 and the autoantibody thereof in a subject. Said complex can be measured by measuring the obtained immune complex of the aforementioned complex, reaginic antibody, and substance capable of binding with the autoantibody of Ku86. As a consequence, it is possible to determine whether the cancer is a primary hepatoma, colon cancer, stomach cancer, pancreatic cancer, breast cancer, lung cancer, or an esophageal cancer.
    Type: Application
    Filed: February 7, 2011
    Publication date: December 6, 2012
    Applicant: NITTO BOSEKI CO., LTD.
    Inventors: Ryo Kojima, Kenta Noda, Masanori Seimiya, Kazuyuki Sogawa, Fumio Nomura
  • Publication number: 20120282638
    Abstract: An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma.
    Type: Application
    Filed: January 18, 2011
    Publication date: November 8, 2012
    Inventors: Ryo Kojima, Kenta Noda, Masanori Seimiya, Kazuyuki Sogawa, Fumio Nomura
  • Publication number: 20120276562
    Abstract: Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the ?-E chain and ? chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.
    Type: Application
    Filed: October 13, 2010
    Publication date: November 1, 2012
    Applicant: Nitto Boseki Co., Ltd.
    Inventors: Wataru Kikuchi, Momoe Sato, Kenta Noda, Iwao Kiyokawa, Toshihide Miura, Ryo Kojima, Fumio Nomura, Kazuyuki Sogawa
  • Publication number: 20110108722
    Abstract: A method of detecting an abnormal amount of a biomarker associated with biliary tract cancer in a subject can comprise: a) quantitating an amount of a fragment of prothrombin having an m/z value of about 4204 m/z in a biological sample from the subject; and b) comparing the quantitated value obtained in (a) with a threshold value.
    Type: Application
    Filed: November 2, 2010
    Publication date: May 12, 2011
    Inventors: Shintaro Kikkawa, Kazuyuki Sogawa, Osamu Yokosuka, Fumio Nomura
  • Patent number: 7781180
    Abstract: Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen ?-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: August 24, 2010
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Fumio Nomura, Kazuyuki Sogawa, Takeshi Tomonaga, Takenori Ochiai, Hideaki Shimada, Tatsuya Ohashi, Katsuhiro Katayama
  • Publication number: 20090275059
    Abstract: Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen ?-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
    Type: Application
    Filed: March 4, 2009
    Publication date: November 5, 2009
    Applicant: NITTO BOSEKI CO., LTD.
    Inventors: Fumio Nomura, Kazuyuki Sogawa, Takeshi Tomonaga, Takenori Ochiai, Hideaki Shimada, Tatsuya Ohashi, Katsuhiro Katayama
  • Patent number: 7517951
    Abstract: Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen ?-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: April 14, 2009
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Fumio Nomura, Kazuyuki Sogawa, Takeshi Tomonaga, Takenori Ochiai, Hideaki Shimada, Tatsuya Ohashi, Katsuhiro Katayama
  • Publication number: 20060116504
    Abstract: Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen ?-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
    Type: Application
    Filed: December 24, 2003
    Publication date: June 1, 2006
    Applicant: Nitto Boseki Co., Ltd.
    Inventors: Fumio Nomura, Kazuyuki Sogawa, Takeshi Tomonaga, Takenori Ochiai, Hideaki Shimada, Tatsuya Oshashi, Katsuhiro Katayama